SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-011217 to HYPERION DEFI, INC. (HYPD)

HYPERION DEFI, INC.
Date: Oct. 4, 2024 · CIK: 0001682639 · Accession: 0000000000-24-011217

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-282458

Date
October 4, 2024
Author
Not clearly detected
Form
UPLOAD
Company
HYPERION DEFI, INC.

Letter

October 4, 2024 Michael Rowe Chief Executive Officer Eyenovia, Inc. 295 Madison Avenue, Suite 2400 New York, New York 10017 Re:Eyenovia, Inc. Registration Statement on Form S-3 Filed October 1, 2024 File No. 333-282458 Dear Michael Rowe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Julie M. Plyler

Show Raw Text
October 4, 2024
Michael Rowe
Chief Executive Officer
Eyenovia, Inc.
295 Madison Avenue, Suite 2400
New York, New York 10017
Re:Eyenovia, Inc.
Registration Statement on Form S-3
Filed October 1, 2024
File No. 333-282458
Dear Michael Rowe:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Julie M. Plyler